Upadacitinib

NEW ORLEANS — Phase 2 clinical trial results confirmed the benefit of upadacitinib, a selective Janus kinase 1 inhibitor, in the treatment of hidradenitis suppurativa, according to a presentation here.

In a Healio video exclusive, Remo Panaccione, MD, noted the cumulative benefit of Skyrizi and Rinvoq for the induction and maintenance treatment of patients with inflammatory bowel disease.

MIAMI BEACH, Fla. — The past year has seen explosive development in Janus kinase inhibitors for dermatologic conditions, and it is possible they could continue to have indications throughout the specialty, according to a speaker here.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses how ulcerative colitis impacts pregnancy.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses recent approvals for ulcerative colitis.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses recent COVID-19 has impacted ulcerative colitis care.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses the unmet needs of patients with ulcerative colitis.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses the long-term effects of ulcerative colitis treatment for younger patients.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses recent how to choose the right ulcerative colitis treatment for the right patient.

PHILADELPHIA — Patients with rheumatoid arthritis who were treated with upadacitinib demonstrated improvement in pain, fatigue and morning stiffness from week 1 through week 12, according to data presented at ACR Convergence 2022.